NCT06765785

Cardiovascular Screening in Asymptomatic South Asians

Not yet recruiting NA Last updated 10 January 2025

What this trial tests

NA trial testing CTCA in Cardiovascular Diseases in 50 participants. Not yet recruiting.

Timeline

31 December 2024

Primary endpoint
31 December 2026

31 July 2027

Quick facts

Lead sponsor	Sandwell & West Birmingham Hospitals NHS Trust
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	31 December 2024
Primary completion	31 December 2026
Estimated completion	31 July 2027

Drugs / interventions tested

• CTCA

Conditions studied

• Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
• Asymptomatic Condition — all drugs for Asymptomatic Condition →
• South Asian — all drugs for South Asian →

Sponsor

Sandwell & West Birmingham Hospitals NHS Trust

Who can join

Adults 30 to 60, any sex, with Cardiovascular Diseases or Asymptomatic Condition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiovascular disease (CVD) is the leading cause of morbidity, mortality and healthcare costs in the United Kingdom. Ethnic minorities like South Asians (SA) have a 3-5 times higher incidence of CVD as predicted by various risk scores despite similar or fewer traditional cardiovascular risk factors.

Computed Tomography Coronary Angiography (CTCA) is able to outline the coronary anatomy determining the site, severity and type of atherosclerotic plaque location in the heart arteries. The National Institute for Health and Care Excellence (NICE) guidelines recommends CTCA as the first line investigation for stable chest pain considered to be coming from the heart (angina).

However there is no pathway for the patients who are asymptomatic but at high risk of CVD, such as the SA cohort. Current practice involves using risk scores to guide management of asymptomatic adults. One recommended and commonly used score is the Q-risk score (the QRISK ® 3-2018 risk calculatorhttps://qrisk.org \> three). This score incorporates ethnicity amongst other risk factors and patients with a risk ≥10% of having a heart attack or stroke in the next 10 years are offered primary prevention treatment with low dose statin therapy. For example, an average (height 164cm weight 70kg) 40 year old male of SA descent, without symptoms who is a non-smoker but with Diabetes Mellitus (DM) on tablet treatment scores 5.8% - this risk is not high enough to warrant treatment with a statin unless he also has abnormally raised cholesterol levels. But this patient is still high risk of CVD due to his ethnicity and DM. There is no current evidence to tailor treatment in such asymptomatic, high risk ethnic minorities.

Similar to screening programs for cancer, screening CTCA, compared to risk stratification with the QRISK ® 3 score, may help in risk stratification of a higher proportion of SA patients. 50 asymptomatic SA patients from 2 sites (25 patients each site) with one CV risk factor will be randomised to either Q-risk 3 score or to screening CTCA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.